Dechert Advises Affluent Medical on Caranx Medical and Artedrone Acquisitions and a Simultaneous Fundraising

Dechert advised Affluent Medical, a French clinical-stage MedTech company focused on innovative implantable medical devices, on entering into binding agreements to acquire Caranx Medical and Artedrone. The transactions will be fully settled in newly issued shares and include earn-out mechanisms. Dechert also advised on a simultaneous fundraising of up to €30 million led by Truffle Capital and Edwards Lifesciences.

Completion of the acquisitions is expected by the end of January 2026, subject to approvals at the Extraordinary General Meeting scheduled for 30 January 2026. The deal is part of a plan to combine the three companies under the name “Carvolix.”

Affluent Medical was advised by Vianney Toulouse, with support from Mathilde Duchamp and Anais Fritzinger of  the M&A and capital markets team dedicated to life sciences, led by Alain Decombe. Labor law advice was provided by national partner Thibault Meiers.

About Dechert

Dechert is the law firm that helps business leaders lead.

For more than 150 years, we have advised clients on critical issues – from first-in-market transaction structures and complex regulatory matters to high-stakes litigation. Our lawyers in commercial centers worldwide are immersed in the key sectors we serve – financial services, private capital, real estate, life sciences and technology. Dechert delivers unwavering partnership so our clients can achieve unprecedented results.

Dechert’s Paris office is a key component of the firm's strategy in Europe and is active in antitrust/competition and European law, corporate/M&A, financial services & asset management, financing, intellectual property, labor and employment, litigation and compliance, regulatory and tax.

Dechert’s life sciences team in France represents companies ranging from multinational giants to emerging companies involving all aspects of the life sciences industry, including pharmaceuticals, biotechnology, drug discovery, genomics, biopharmaceuticals, diagnostics, medical devices and health care. We also assist investment funds with life sciences investments. Read more »